Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.
Enanta Pharmaceuticals, Inc. develops small-molecule drugs for viral infections and immunological diseases through a chemistry-driven drug discovery approach. News about the company commonly covers its respiratory syncytial virus programs, including zelicapavir, an oral N-protein inhibitor, and EDP-323, an L-protein inhibitor, as well as clinical data presentations at medical and scientific conferences.
Enanta updates also focus on immunology programs targeting drivers of type 2 immune responses, including KIT, STAT6 and MRGPRX2 inhibition. Company releases frequently address candidates such as EDP-978 and EPS-3903, research and development progress, quarterly financial results, management conference participation and royalty revenue tied to its collaboration history.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced key developments for 2022 during the J.P. Morgan Healthcare Conference on January 11. The company plans to initiate a Phase 1 study of EDP-235, a COVID-19 treatment, in February 2022. Additionally, enrollment is complete for the Phase 2 RSVP study of EDP-938 for RSV, with data expected in Q2 2022. Enanta also introduced EDP-323, a new RSV candidate, aiming for a Phase 1 study in H2 2022. The company remains focused on advancing its virology pipeline and addressing urgent healthcare needs amid ongoing challenges from emerging COVID-19 variants.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced that CEO Jay R. Luly, Ph.D., will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 3:00 p.m. ET. A live webcast will be available on Enanta's website under the 'Events and Presentations' section, with a replay accessible for 30 days post-event.
Enanta focuses on developing small molecule drugs for viral infections and liver diseases, including clinical candidates for RSV, HBV, and COVID-19. Their R&D is funded by royalties from HCV products developed with AbbVie, including the notable drug MAVYRET®.
Enanta Pharmaceuticals has presented first preclinical data for EDP-235, an oral protease inhibitor targeting COVID-19, and reported positive Phase 1b results for EDP-514 in chronic HBV patients. The company terminated the development of EDP-721 due to safety concerns. For the fiscal year ended September 30, 2021, total revenue was $97.1 million, down from $122.5 million in 2020, primarily from unchanged royalty revenue of $23.6 million. Enanta recorded a net loss of $79.0 million for the year. The company expects sufficient cash to meet operational needs for at least two years.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced participation in two virtual investor conferences in December 2021. Jay R. Luly, President and CEO, will speak at the Evercore ISI HealthCONx Conference on December 1, 2021, at 10:30 a.m. ET, and will also present at the Piper Sandler Healthcare Conference on December 2, 2021. A pre-recorded chat will be available to attendees on November 29, 2021. Webcasts will be accessible on Enanta's website and archived for 14 days.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced the discontinuation of EDP-721, an oral HBV RNA destabilizer, due to safety concerns raised in a Phase 1 study. Despite a promising preclinical safety profile, emerging safety signals prompted the decision to prioritize patient safety. The company remains focused on EDP-514, a core inhibitor for HBV, which has shown robust antiviral activity in earlier trials. Enanta aims to develop a functional cure for chronic hepatitis B, leveraging its drug discovery capabilities and ongoing research efforts.
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) will release its fiscal fourth-quarter and full-year financial results on November 22, 2021, after market close. A conference call is scheduled for 4:30 p.m. ET to discuss the results and updates on their R&D pipeline, which includes candidates for RSV, HBV, and COVID-19. The company continues to fund its R&D through royalties from its collaboration with AbbVie on HCV products, specifically the protease inhibitor Glecaprevir.
Enanta Pharmaceuticals announces positive results from the final Phase 1b data of EDP-514, a new hepatitis B virus core inhibitor. At 800 mg, EDP-514 was shown to be safe and well-tolerated over 28 days, with robust antiviral activity reflected in a 3.5 log decline in HBV DNA in viremic patients. EDP-514's pharmacokinetics support once-daily oral dosing, paving the way for combination therapy strategies. The data was presented at The Liver Meeting® 2021, showcasing the potential of EDP-514 for chronic HBV treatment.
Enanta Pharmaceuticals (NASDAQ:ENTA) has released preclinical data for EDP-235, an oral protease inhibitor targeting COVID-19. The data, presented at the ISIRV-WHO Virtual Conference, shows EDP-235's potent inhibition of SARS-CoV-2, with an IC50 of 5.8 nM and effective action against variants. The drug demonstrated promising pharmacokinetic properties, including 95% oral bioavailability and a projected half-life of 16 hours, indicating potential for once-daily dosing. Enanta plans to advance EDP-235 into clinical studies in early 2022.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced that new preclinical data for EDP-235, its lead oral protease inhibitor for COVID-19, will be presented at the ISIRV-WHO Virtual Conference from October 19-21, 2021. The poster presentation titled “EDP-235, A Potential Oral, Once-Daily Antiviral Treatment and Preventative for COVID-19” will be showcased on October 19 at 8:00 a.m. CET, presented by Li-Juan Jiang, Ph.D. The company continues to focus on developing antiviral treatments, supported by royalties from its collaboration with AbbVie for hepatitis C virus products.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced that CEO Jay R. Luly, Ph.D., will participate in a fireside chat on October 13, 2021, at 3:30 p.m. ET during the H.C. Wainwright 2nd Annual Hepatitis B Virus Virtual Conference. A live webcast of the presentation can be accessed on Enanta’s website, with replays available for 30 days post-event. Enanta focuses on small molecule drug discovery for viral infections and liver diseases, including candidates for respiratory syncytial virus, hepatitis B virus, and COVID-19.